MeSH term
Frequency | Condition_Probility | Animals | 26 | 0.0 |
Humans | 139 | 0.0 |
Research Support, Non-U.S. Gov't | 77 | 0.0 |
Antibodies/pharmacology | 4 | 1.0 |
Antineoplastic Agents, Alkylating/*metabolism | 2 | 28.0 |
*Aryl Hydrocarbon Hydroxylases | 27 | 3.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*metabolism | 12 | 9.0 |
Enzyme Inhibitors/pharmacology | 10 | 0.0 |
Isoenzymes/antagonists & inhibitors/metabolism | 8 | 11.0 |
Kinetics | 33 | 0.0 |
Microsomes, Liver/drug effects/*enzymology | 6 | 13.0 |
Mixed Function Oxygenases/antagonists & inhibitors/*metabolism | 5 | 10.0 |
Transfection | 11 | 0.0 |
Aged | 12 | 0.0 |
Cells, Cultured | 13 | 0.0 |
Cytochrome P-450 Enzyme System/genetics/*metabolism | 10 | 6.0 |
Female | 25 | 0.0 |
Hepatocytes/*enzymology | 2 | 13.0 |
Rifampin/pharmacology | 3 | 4.0 |
Sensitivity and Specificity | 2 | 0.0 |
Enzyme Inhibitors/*pharmacology | 7 | 0.0 |
Tumor Cells, Cultured | 9 | 0.0 |
Chromatography, High Pressure Liquid | 16 | 0.0 |
Cytochrome P-450 Enzyme System/genetics/immunology/*metabolism | 2 | 33.0 |
DNA, Complementary/genetics | 2 | 0.0 |
In Vitro | 34 | 0.0 |
Microsomes, Liver/enzymology/metabolism | 5 | 7.0 |
Mixed Function Oxygenases/genetics/*metabolism | 3 | 6.0 |
Rats | 11 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 31 | 0.0 |
Spectrometry, Mass, Electrospray Ionization | 2 | 2.0 |
Substrate Specificity | 16 | 0.0 |
Variation (Genetics) | 3 | 0.0 |
Anti-Infective Agents/*pharmacology | 2 | 6.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/metabolism | 5 | 7.0 |
Male | 21 | 0.0 |
Microsomes, Liver/drug effects/enzymology | 9 | 9.0 |
Recombinant Proteins/antagonists & inhibitors | 4 | 8.0 |
*Steroid 16-alpha-Hydroxylase | 17 | 9.0 |
Steroid Hydroxylases/*antagonists & inhibitors/metabolism | 2 | 22.0 |
Cytochrome P-450 Enzyme System/chemistry/*metabolism | 3 | 16.0 |
Isoenzymes/chemistry/metabolism | 2 | 7.0 |
Models, Molecular | 6 | 0.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors | 3 | 2.0 |
Adolescent | 3 | 0.0 |
Adult | 17 | 0.0 |
Aged, 80 and over | 3 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
Isoenzymes/*metabolism | 4 | 1.0 |
Middle Aged | 13 | 0.0 |
Species Specificity | 5 | 0.0 |
Comparative Study | 20 | 0.0 |
Escherichia coli | 2 | 0.0 |
Microsomes, Liver/metabolism | 6 | 3.0 |
Oxidation-Reduction | 13 | 0.0 |
Biotransformation | 16 | 2.0 |
Cytochrome P-450 Enzyme System/*metabolism | 21 | 4.0 |
Hydroxylation | 18 | 5.0 |
Mixed Function Oxygenases/*metabolism | 6 | 4.0 |
Recombinant Proteins/metabolism | 17 | 0.0 |
Steroid Hydroxylases/*metabolism | 5 | 15.0 |
Structure-Activity Relationship | 5 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*metabolism | 3 | 6.0 |
Cross-Over Studies | 2 | 0.0 |
Drug Interactions | 11 | 0.0 |
Rifampin/*pharmacology | 2 | 4.0 |
Dealkylation | 6 | 10.0 |
Microsomes, Liver/enzymology | 11 | 5.0 |
Steroid Hydroxylases/antagonists & inhibitors/*metabolism | 3 | 33.0 |
Diclofenac/metabolism | 2 | 14.0 |
Dose-Response Relationship, Drug | 9 | 0.0 |
Liver/*enzymology | 3 | 0.0 |
Steroid Hydroxylases/antagonists & inhibitors | 2 | 20.0 |
Aryl Hydrocarbon Hydroxylases/*genetics | 3 | 2.0 |
Exons | 2 | 0.0 |
Cytochrome P-450 Enzyme System/*genetics | 4 | 0.0 |
Liver/drug effects/enzymology/metabolism | 2 | 16.0 |
Microsomes, Liver/drug effects/enzymology/metabolism | 2 | 6.0 |
Spectrophotometry, Ultraviolet | 2 | 1.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Coumarins/metabolism | 2 | 8.0 |
Cytochrome P-450 Enzyme System/*genetics/metabolism | 4 | 3.0 |
NADP/metabolism | 2 | 1.0 |
NADPH-Ferrihemoprotein Reductase/*genetics/metabolism | 2 | 40.0 |
Recombinant Proteins/genetics/metabolism | 6 | 0.0 |
Salmonella typhimurium/*genetics | 3 | 42.0 |
Microsomes, Liver/drug effects/*enzymology/metabolism | 2 | 22.0 |
Rats, Wistar | 3 | 0.0 |
DNA, Complementary/biosynthesis | 4 | 7.0 |
Isoenzymes/metabolism | 6 | 1.0 |
Microsomes, Liver/enzymology/*metabolism | 6 | 7.0 |
Blotting, Western | 6 | 0.0 |
Carcinoma, Hepatocellular | 2 | 0.0 |
Catalysis | 10 | 1.0 |
Mice | 6 | 0.0 |
Oxidoreductases, N-Demethylating/*metabolism | 2 | 2.0 |
Saccharomyces cerevisiae/enzymology | 2 | 3.0 |
Genetic Engineering | 2 | 2.0 |
Mutagenicity Tests | 2 | 1.0 |
NADPH-Ferrihemoprotein Reductase/genetics/metabolism | 2 | 28.0 |
DNA, Complementary/metabolism | 5 | 0.0 |
Liver/metabolism | 5 | 0.0 |
Models, Chemical | 3 | 0.0 |
Phenotype | 4 | 0.0 |
Protein Binding | 4 | 0.0 |
Time Factors | 3 | 0.0 |
Gene Expression | 4 | 0.0 |
Isoenzymes/antagonists & inhibitors/genetics/*metabolism | 2 | 14.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Plasmids/genetics | 2 | 0.0 |
Ultrafiltration | 2 | 3.0 |
Cell Line | 6 | 0.0 |
Dexamethasone/pharmacology | 3 | 0.0 |
Enzyme Induction/drug effects | 4 | 1.0 |
Immunoblotting | 5 | 0.0 |
Isoenzymes/genetics/metabolism | 3 | 2.0 |
Liver/enzymology/metabolism | 2 | 6.0 |
Phenobarbital/pharmacology | 3 | 4.0 |
Receptors, Cytoplasmic and Nuclear/metabolism | 2 | 1.0 |
Receptors, Steroid/metabolism | 2 | 4.0 |
Administration, Oral | 2 | 0.0 |
Alleles | 3 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*genetics/metabolism | 2 | 5.0 |
Genotype | 4 | 0.0 |
Metabolic Clearance Rate | 2 | 0.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Prospective Studies | 2 | 0.0 |
Ditiocarb/*pharmacology | 2 | 25.0 |
Plasmids | 2 | 0.0 |
Microsomes, Liver/*enzymology | 9 | 4.0 |
Inhibitory Concentration 50 | 4 | 1.0 |
Blotting, Northern | 2 | 0.0 |
Midazolam/metabolism | 2 | 10.0 |
Sulfaphenazole/pharmacology | 3 | 10.0 |
Hydroxylation/drug effects | 2 | 5.0 |
Microsomes, Liver/drug effects/*metabolism | 2 | 5.0 |
Troleandomycin/pharmacology | 2 | 3.0 |
Molecular Sequence Data | 6 | 0.0 |
Tretinoin/*metabolism | 2 | 4.0 |
Isoenzymes/antagonists & inhibitors/*metabolism | 3 | 8.0 |
Protein Conformation | 2 | 0.0 |
Rabbits | 5 | 0.0 |
Antimetabolites, Antineoplastic/*pharmacology | 2 | 2.0 |
Antineoplastic Agents/*pharmacology | 3 | 0.0 |
Fluorouracil/*pharmacology | 3 | 7.0 |
Forecasting | 2 | 0.0 |
*Gene Expression Profiling | 2 | 0.0 |
*Models, Theoretical | 2 | 3.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Predictive Value of Tests | 2 | 0.0 |
Regression Analysis | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 8 | 0.0 |
Stomach Neoplasms/*drug therapy/*genetics | 2 | 100.0 |
Gene Expression Regulation | 2 | 0.0 |
Steroid Hydroxylases/*genetics | 2 | 2.0 |
Arachidonic Acid/metabolism | 2 | 2.0 |
Dogs | 2 | 0.0 |
Haplorhini | 2 | 0.0 |
Liver/*metabolism | 2 | 0.0 |
Microsomes, Liver/*enzymology/metabolism | 4 | 13.0 |
*Thiazolidinediones | 2 | 2.0 |
Cross Reactions | 2 | 0.0 |
Ketoconazole/pharmacology | 4 | 4.0 |
Pharmaceutical Preparations/*metabolism | 3 | 3.0 |
Testosterone/metabolism | 2 | 1.0 |
Hypnotics and Sedatives/*metabolism | 3 | 42.0 |
Piperazines/*metabolism | 2 | 40.0 |
Aryl Hydrocarbon Hydroxylases/genetics/*metabolism | 2 | 8.0 |
Base Sequence | 3 | 0.0 |
Binding Sites | 2 | 0.0 |
DNA Primers | 3 | 0.0 |
Paclitaxel/metabolism | 3 | 37.0 |
Sulfonamides/metabolism | 2 | 28.0 |
Cytochrome P-450 CYP2D6/metabolism | 2 | 5.0 |
English Abstract | 2 | 0.0 |
Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Pyrimidines/*metabolism | 2 | 28.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Risk Factors | 2 | 0.0 |
Polymerase Chain Reaction | 3 | 0.0 |
RNA, Messenger/metabolism | 5 | 0.0 |
Xenobiotics/*metabolism | 3 | 5.0 |
Amino Acid Sequence | 3 | 0.0 |
Antibodies, Viral/immunology | 2 | 2.0 |
Biopsy | 2 | 0.0 |
Bone Neoplasms/pathology/virology | 2 | 33.0 |
Carcinoma, Squamous Cell/etiology/*genetics/pathology/virology | 2 | 33.0 |
Cell Differentiation | 2 | 0.0 |
Cell Line, Tumor/metabolism/virology | 2 | 28.0 |
Cell Nucleus/virology | 2 | 15.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
Cell Transformation, Viral/genetics | 2 | 8.0 |
Cervical Intraepithelial Neoplasia/etiology/*genetics/pathology/virology | 2 | 33.0 |
Cervix Neoplasms/etiology/*genetics/pathology/virology | 2 | 33.0 |
Cervix Uteri/pathology/*virology | 2 | 28.0 |
Disease Progression | 2 | 0.0 |
Epithelial Cells/ultrastructure/virology | 2 | 33.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
*Gene Expression Regulation, Viral | 2 | 0.0 |
Genes, Retinoblastoma | 2 | 2.0 |
Oncogene Proteins, Viral/biosynthesis/genetics/immunology/*physiology | 2 | 33.0 |
Osteosarcoma/pathology/virology | 2 | 33.0 |
Papillomavirus Infections/*genetics | 2 | 25.0 |
Papillomavirus, Human/genetics/*pathogenicity | 2 | 25.0 |
Retinoblastoma Protein/*metabolism | 2 | 1.0 |
Tumor Virus Infections/*genetics | 2 | 18.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*physiology | 2 | 13.0 |
DNA, Complementary | 3 | 0.0 |
Microsomes, Liver/*metabolism | 6 | 3.0 |
Cytochrome P-450 Enzyme System/*physiology | 3 | 5.0 |
Linear Models | 2 | 0.0 |
Cytochrome P-450 Enzyme System/biosynthesis/genetics/*metabolism | 2 | 12.0 |
Cytochrome P-450 Enzyme System/metabolism | 2 | 0.0 |
Glucuronosyltransferase/metabolism | 2 | 7.0 |
Arachidonic Acid/*metabolism | 2 | 5.0 |
Mass Fragmentography | 3 | 1.0 |
Stereoisomerism | 3 | 0.0 |
Ifosfamide/*metabolism | 2 | 50.0 |
Area Under Curve | 2 | 0.0 |
Isoenzymes/*physiology | 2 | 6.0 |
Mixed Function Oxygenases/metabolism | 2 | 1.0 |
Cytochrome P-450 CYP2E1 | 2 | 1.0 |
Ethylene Glycols/metabolism | 2 | 40.0 |
Styrene | 2 | 28.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Methylation | 2 | 0.0 |
Fluorometry | 2 | 2.0 |
Microsomes/metabolism | 4 | 3.0 |
Isoenzymes/genetics/*metabolism | 2 | 2.0 |
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors/*biosynthesis | 2 | 66.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*biosynthesis | 2 | 33.0 |
DNA, Complementary/analysis | 2 | 0.0 |
Insects | 3 | 1.0 |
Pharmaceutical Preparations/metabolism | 2 | 6.0 |
Oxidoreductases, N-Demethylating/genetics/metabolism | 2 | 11.0 |
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors/*metabolism | 2 | 25.0 |
Gene Frequency | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
